CSHS WWW HOME | MS EXCHANGE LOG ON | PULSE ARCHIVES
Medical Staff Pulse is
a Publication of the Chief of Staff
Pharmacy Focus

FDA Issues Clarification Regarding Rocephin - Calcium Interaction

Roche has informed healthcare professionals about revisions made to the prescribing information for Rocephin to clarify the potential risk associated with concomitant use of Rocephin with calcium or calcium-containing solutions or products.

Healthcare professionals are advised that Rocephin and calcium-containing solutions, including continuous calcium-containing infusions such as parenteral nutrition, should not be mixed or co-administered to any patient irrespective of age, even via different infusion lines at different sites.

Rocephin and IV calcium-containing solutions should not be administered within 48 hours of each other in any patient. No data is available on the potential interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral).